Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

AACR 2017

1 - 5 Apr 2017
Walter E. Washington Convention Center, Washington, D.C., United States of America
Videos
News
Global horizons of the WIN consortium
Dr Vladimir Lazar - Chief Operating Officer, WIN Consortium
Global horizons of the WIN consortium ( Dr Vladimir Lazar - Chief Operating Officer, WIN Consortium )
27 Apr 2017
What is the WIN Consortium?
Dr John Mendelsohn - Chairman of the WIN Consortium
What is the WIN Consortium? ( Dr John Mendelsohn - Chairman of the WIN Consortium )
27 Apr 2017
Pembrolizumab and indoximod for melanoma
Prof Yousef Nabih Zakharia - Holden Comprehensive Cancer Center, University of...
Pembrolizumab and indoximod for melanoma ( Prof Yousef Nabih Zakharia - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA )
13 Apr 2017
Projections of cancer incidence and burden among the HIV-positive population in...
Jessica Yasmine Islam - University of North Carolina, Chapel Hill, USA
Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030 ( Jessica Yasmine Islam - University of North Carolina, Chapel Hill, USA )
12 Apr 2017
Nivolumab for NSCLC: five years on
Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Nivolumab for NSCLC: five years on ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
12 Apr 2017
Avelumab for metastatic Merkel cell carcinoma after chemotherapy
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Avelumab for metastatic Merkel cell carcinoma after chemotherapy ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
Nivolumab and ipilimumab combination for advanced skin cancer
Dr James Larkin - The Royal Marsden, London, UK
Nivolumab and ipilimumab combination for advanced skin cancer ( Dr James Larkin - The Royal Marsden, London, UK )
12 Apr 2017
Long-term clinical outcomes and analyses of atezolizumab for mTNBC
Prof Peter Schmid - Barts Cancer Institute, London, UK
Long-term clinical outcomes and analyses of atezolizumab for mTNBC ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
12 Apr 2017
Checkmate 067 - combined nivolumab and ipilimumab
Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Checkmate 067 - combined nivolumab and ipilimumab ( Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
12 Apr 2017
Glycemia positively associated with prostate cancer mortality in non-diabetic...
Michael Marrone - Johns Hopkins University, Baltimore, USA
Glycemia positively associated with prostate cancer mortality in non-diabetic men ( Michael Marrone - Johns Hopkins University, Baltimore, USA )
12 Apr 2017
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors
Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors ( Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA )
12 Apr 2017
Durable responses to avelumab in patients with Merkel cell carcinoma
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Durable responses to avelumab in patients with Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker...
Prof Peter Schmid - Barts Cancer Institute, London, UK
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
11 Apr 2017
Five-year follow-up of nivolumab in NSCLC
Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Five-year follow-up of nivolumab in NSCLC ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
11 Apr 2017
Mutations in cancer predisposition genes and risk for subsequent neoplasms
Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA
Mutations in cancer predisposition genes and risk for subsequent neoplasms ( Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA )
11 Apr 2017
Final overall survival analysis of MONARCH 1
Dr Hope Rugo - UCSF Medical Center, San Francisco, USA
Final overall survival analysis of MONARCH 1 ( Dr Hope Rugo - UCSF Medical Center, San Francisco, USA )
11 Apr 2017
Redefining tamoxifen for breast cancer
Gokul Das - Roswell Park Cancer Institute, Buffalo, USA
Redefining tamoxifen for breast cancer ( Gokul Das - Roswell Park Cancer Institute, Buffalo, USA )
11 Apr 2017
Olaparib and temozolomide for relapsed small cell lung cancer
Dr Anna Farago - Massachusetts General Hospital, Boston, USA
Olaparib and temozolomide for relapsed small cell lung cancer ( Dr Anna Farago - Massachusetts General Hospital, Boston, USA )
10 Apr 2017
Treatment choices for HER2 amplified colorectal cancer
Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Treatment choices for HER2 amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Final results of the HERACLES trial in HER2-amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid...
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Neratinib in HER2 or HER3 mutant solid tumours
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Neratinib in HER2 or HER3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Understanding response and resistance to cancer therapy: Lessons learned from...
Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston...
Understanding response and resistance to cancer therapy: Lessons learned from melanoma ( Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Apr 2017
Tumour-treating fields complement chemotherapy in aggressive brain tumours
Prof Roger Stupp - Northwestern University, Chicago, USA
Tumour-treating fields complement chemotherapy in aggressive brain tumours ( Prof Roger Stupp - Northwestern University, Chicago, USA )
10 Apr 2017
Tumour treating fields added to standard chemotherapy in newly diagnosed...
Prof Roger Stupp - Northwestern University, Chicago, USA
Tumour treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): ( Prof Roger Stupp - Northwestern University, Chicago, USA )
10 Apr 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation